Outcome following lung resections for pT1 non-small cell lung cancer

Kopp, Ray Manneh; Weidenhagen, R.; Reinmiedl, J.; Müller, Ch.; Fürst, H.; Bittmann, Iris; Dienemann, Hendrik; Hatz, Rudolf

doi:10.1016/j.ejso.2005.11.019

Cited by 5 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the average patient with a diagnosis of lung cancer the overall 5-year survival rates have increased from 12% in the early 70s to 15% in 2001 [2]. Survival ranges from 75% for patients with pT1N0 disease to virtually nil for patients with stage IV non-small cell lung cancer (NSCLC) [3]. Surgery with curative intent represents the best chance for cure, but is only an option in patients with stages I, II, and selected cases of stage IIIA (T 3 N 1 M 0 ) NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Biological correlates of FDG uptake in non-small cell lung cancer

et al. 2007

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Biological correlates of FDG uptake in non-small cell lung cancer

et al. 2007

View full text Add to dashboard Cite

“…However, the survival rates following curative resection for clinical and pathologic stage I lung adenocarcinoma are <50% and <75%, respectively (11,12). The most common cause of treatment failure is disease recurrence.…”

Section: Introductionmentioning

confidence: 99%

Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma

Choi

Kim

Sung

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To better understand the complete genomic architecture of lung adenocarcinoma.Experimental Design: We used array experiments to determine copy number variations and sequenced the complete exomes of the 247 lung adenocarcinoma tumor samples along with matched normal cells obtained from the same patients. Fully annotated clinical data were also available, providing an unprecedented opportunity to assess the impact of genomic alterations on clinical outcomes.Results: We discovered that genomic alternations in the RB pathway are associated with significantly shorter disease-free survival in early-stage lung adenocarcinoma patients. This association was also observed in our independent validation cohort. The current treatment guidelines for early-stage lung adenocarcinoma patients recommend follow-up without adjuvant therapy after complete resection, except for high-risk patients. However, our findings raise the interesting possibility that additional clinical interventions might provide medical benefits to early-stage lung adenocarcinoma patients with genomic alterations in the RB pathway. When examining the association between genomic mutation and histologic subtype, we uncovered the characteristic genomic signatures of various histologic subtypes. Notably, the solid and the micropapillary subtypes demonstrated great diversity in the mutated genes, while the mucinous subtype exhibited the most unique landscape. This suggests that a more tailored therapeutic approach should be used to treat patients with lung adenocarcinoma.Conclusions: Our analysis of the genomic and clinical data for 247 lung adenocarcinomas should help provide a more comprehensive genomic portrait of lung adenocarcinoma, define molecular signatures of lung adenocarcinoma subtypes, and lead to the discovery of useful prognostic markers that could be used in personalized treatments for early-stage lung adenocarcinoma patients.

show abstract